Dosimetric Selection for Helical Tomotherapy Based Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer or Lung Metastases

@article{Chi2012DosimetricSF,
  title={Dosimetric Selection for Helical Tomotherapy Based Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer or Lung Metastases},
  author={A. Chi and Z. Liao and N. Nguyen and J. Xu and J. Welsh and Si Young Jang and C. Howe and R. Komaki},
  journal={PLoS ONE},
  year={2012},
  volume={7}
}
  • A. Chi, Z. Liao, +5 authors R. Komaki
  • Published 2012
  • Medicine
  • PLoS ONE
  • Background No selection criteria for helical tomotherapy (HT) based stereotactic ablative radiotherapy (SABR) to treat early stage non-small cell lung cancer (NSCLC) or solitary lung metastases has been established. In this study, we investigate the dosimetric selection criteria for HT based SABR delivering 70 Gy in 10 fractions to avoid severe toxicity in the treatment of centrally located lesions when adequate target dose coverage is desired. Materials and Methods 78 HT-SABR plans for… CONTINUE READING
    Risk factors associated with treatment refusal in lung cancer
    • 14
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 31 REFERENCES
    Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases.
    • 21
    • Open Access
    Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
    • 265
    • Highly Influential
    Stereotactic body radiation therapy for lung metastases.
    • 114